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Abstract
Introduction: Connective Tissue Diseases (CTDs) are systemic autoimmune conditions characterized by frequent
lung involvement. This usually takes the form of Interstitial Lung Disease (ILD), but Obstructive Lung Disease (OLD)
and Pulmonary Artery Hypertension (PAH) can also occur. Lung involvement is often severe, representing the first
cause of death in CTD. The aim of this study is to highlight the role of Pulmonary Function Tests (PFTs) in the
diagnosis and follow up of CTD patients.
Main body: Rheumatoid Arthritis (RA) showed mainly an ILD with a Usual Interstitial Pneumonia (UIP) pattern in
High-Resolution Chest Tomography (HRCT). PFTs are able to highlight a RA-ILD before its clinical onset and to drive
follow up of patients with Forced Vital Capacity (FVC) and Carbon Monoxide Diffusing Capacity (DLCO). In the
course of Scleroderma Spectrum Disorders (SSDs) and Idiopathic Inflammatory Myopathies (IIMs), DLCO appears to
be more sensitive than FVC in highlighting an ILD, but it can be compromised by the presence of PAH. A restrictive
respiratory pattern can be present in IIMs and Systemic Lupus Erythematosus due to the inflammatory involvement
of respiratory muscles, the presence of fatigue or diaphragm distress.
Conclusions: The lung should be carefully studied during CTDs. PFTs can represent an important prognostic tool
for diagnosis and follow up of RA-ILD, but, on their own, lack sufficient specificity or sensitivity to describe lung
involvement in SSDs and IIMs. Several composite indexes potentially able to describe the evolution of lung damage
and response to treatment in SSDs are under investigation. Considering the potential severity of these conditions,
an HRCT jointly with PFTs should be performed in all new diagnoses of SSDs and IIMs. Moreover, follow up PFTs
should be interpreted in the light of the risk factor for respiratory disease related to each disease.
Keywords: Interstitial lung disease, Rheumatoid arthritis, Connective tissue disease, Antisynthetase Syndrome,
Systemic sclerosis, Sjӧgren Syndrome, Dermatomyositis, Polymyositis, Mixed connective tissue disease, Interstitial
pneumonia with autoimmune features
Background
Connective Tissue Diseases (CTDs) are often character-
ized by pulmonary involvement. The main clinical presen-
tation is Interstitial Lung Disease (ILD), characterized by
an involvement of the lung interstitium with inflammatory
cells and/or exaggerated deposition of extracellular matrix
by myofibroblasts. Pulmonary Artery Hypertension (PAH,
a potentially lethal condition characterized by high blood
pressure in lung arteries) and Obstructive Lung Diseases
(OLDs, an airway obstruction with airflow limitation) can
also occur. These three conditions, with several patho-
genic pathways directly or indirectly related to CTDs can
be present alone or in combination. The lung disease can
be severe, and often represents the main cause of death
for these patients [1]. Currently, Pulmonary Function
Tests (PFTs) in clinical practice appear to be confined to
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the follow up of autoimmune patients in which an estab-
lished lung involvement is known. However, patients can
remain asymptomatic for lung time despite evidence of
lung involvement already being present (“Velcro” crackles
in auscultation, impaired PFTs or evidence of lung in-
volvement in chest imaging) [2, 3]. In view of this, PFTs
can also represent a useful, inexpensive and safe tool for
the diagnosis of lung disease in CTDs and its management
in the early stages, in which the disease could be more
responsive to treatment.
The aim of this paper is to review lung involvement in
CTD and highlight the role of PFTs in its diagnosis and
follow up.
Rheumatoid arthritis
Rheumatoid Arthritis (RA) is an autoimmune, poten-
tially systemic disease characterized by an inflammatory,
symmetric, additive and erosive arthritis affecting about
1% of the population of developed countries [4]. The
pathogenesis of the disease is currently not fully under-
stood, but the lung seems to be a possible source of
autoimmunity. Exposure to dust and smoke can lead to
the citrullination of peptides, provoking an autoimmune
response, with the production of Anti Cyclic Citrulli-
nated Antibodies (ACPA) which represent one of the
most specific items for the diagnosis [5, 6]. Probably due
to autoimmune mechanisms, RA can be directly associ-
ated with respiratory system damage not only with ILD,
but also with bronchiectasis, pleural effusion, rheuma-
toid parenchymal nodules and, rarely, vascular disease.
Indirectly RA-associated respiratory damage (generally
with ILD or respiratory tract infections) can be caused
by the drugs used for treatment [7].
RA-ILD occurs in 4–68% of patients depending on the
criteria used for identification, while 10% of RA patients
showed clinically relevant ILD [8, 9]. The most common
pattern in High-Resolution Chest Tomography (HRCT)
or Surgical Lung Biopsy (SLB) is Usual Interstitial Pneu-
monia (UIP), followed by Nonspecific Interstitial Pneu-
monia (NSIP) and rarely other patterns [7]. Risk factors
linked to RA-ILD are age, male sex, smoking history,
positivity for ACPA, longstanding and/or persistently
active disease, presence of rheumatoid nodules and
articular erosions, and genetic predisposition with
several Human Leukocytes Antigens (HLAs) [10, 11]. A
worse prognosis is reported in UIP pattern rather than
NSIP or Organized Pneumonia (OP), but currently there
is no consensus in the literature on whether a specific
HRCT pattern in RA-ILD has a similar or better prog-
nosis compared to the same pattern in Idiopathic Inter-
stitial Pneumonia (IIP) or Idiopathic Pulmonary Fibrosis
(IPF) [10]. Female sex and higher levels of Carbon
Monoxide Diffusing Capacity (DLCO) were associated
with a better prognosis [12].
RA patients can also develop OLD, mainly Chronic
Obstructive Pulmonary Disease (COPD), Bronchiectasis
(BR) and bronchiolitis associated with ILD. COPD is
obviously the most frequent OLD in RA [13]. A history
of smoking plays a crucial role, but regardless of this,
RA showed a pooled risk ratio of OLD of 1.99 even in
non-smoker patients [14], with a mortality comparable
to RA-ILD [15].
Finally, RA was also associated with Combined Pul-
monary Fibrosis and Emphysema (CPFE), a syndrome
often characterized by severe dyspnoea, preserved lung
volumes and severe reduction of DLCO, with emphysema
localized in the upper lobes and ILD in the lower ones
and possible development of PAH [16]. Initially
described in patients with a history of smoking, it was
described in 27% of RA-ILD patients who had never
smoked and it was independently associated with higher
mortality [17]. PFTs appear to be able to predict the evo-
lution of RA-ILD. Lower Forced Vital Capacity (FVC)
and DLCO and their decline over 6 months are associated
with a severe disease [18], while DLCO ≤54% was identi-
fied as a cut-off for RA-ILD progression with sensitivity
of 80% and specificity of 93% [19]. Another interesting
study correlated mortality with a FVC lower than 61.8%
of that predicted at the baseline or a decline of 10% from
the baseline in any time [20]. In the same study, adjust-
ing data for age, sex and smoking, a specific HRCT pat-
tern was not associated with survival. Instead, the
six-minute walk test (6MWT) during RA-ILD was not
studied in depth, probably due to possible impairment
caused by articular disease.
Despite the fact that pulmonary involvement is the
most common extra-articular manifestation of RA with
an impact on prognosis, guidelines for the management
of lung involvement during RA are not currently avail-
able. Generally, RA patients were studied for lung
involvement at the onset of suggestive symptoms. How-
ever, as already mentioned, several ILDs are able to
produce a decline in PFTs in patients who were initially
asymptomatic [2, 3]. Moreover, a UIP pattern in RA-ILD
is associated with a longer disease duration, leading
some authors to theorise a progression from a NSIP pat-
tern [12]. In view of this concept, it could be useful to
determine ILD before structural damage, in order to
tailor appropriate treatment. Indeed, increasing evidence
suggests the use of anti-fibrotic drugs for the treatment
of RA-ILD [21] and it appears reasonable to suppose
that this could be a new indication for these drugs in the
future.
The recognition of lung involvement in RA can also
be useful in the management of the disease. In fact,
several treatments for RA were associated with the
development or the exacerbation of a pre-existing ILD,
mainly Methotrexate and TNFα blockers [22, 23].
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Patients with RA-ILD may benefit from the use of Toci-
lizumab and Abatacept, two biologic drugs to date not
associated with fibrotic lung involvement [24]. Moreover,
the early recognition of OLD could allow the elimination
of modifiable risk factors, and drive the treatment to-
wards the use of drugs with a lower risk of pulmonary
infections [25].
In our opinion, a physical examination looking for
“Velcro” crackles and PFTs should be performed in
all new diagnoses of RA, and repeated at least every
12 months. HRCT should be reserved for RA patients
with a positive physical examination, impaired PFTs
at baseline or reduction of 10 and 15% respectively
for FVC and DLCO at 6–12 months, according to
international guidelines for IIPs [26].
In the event that the clinical picture suggests CPFE,
the issue of preserved lung volumes would mean that
the only screening possible for these patients would be
based on a clinical examination of their reduced DLCO,
which could then be studied in depth by HRCT and
echocardiogram.
Scleroderma spectrum disorders
The most important disease considered in Scleroderma
Spectrum Disorders (SSDs) is Systemic Sclerosis (SSc).
The disease affects about 1 out of 10,000 persons [27]
and is characterized by fibrosis of the skin and internal
organs, Raynaud Phenomenon (RP) and vasculopathy.
SSc is classically subdivided into 4 expressions according
to skin involvement: Diffuse SSc (dSSc), Limited SSc
(lSSc), SSc sine scleroderma (ssSSc) and Overlap Syn-
dromes (OS), in which classic sclerodermic signs are as-
sociated with features typical of other CTDs [28]. SSc is
the most severe CTD and lung involvement is the major
cause of death both for ILD and PAH [29]. Serological
positivity can serve as a marker of lung involvement:
Scl70 positivity is associated with ILD, while Anticentro-
meric antibodies (ACA), anti RNA polymerase I, II and
III (above all when associated with U1RNP positivity)
are associated with PAH and a worse prognosis. More-
over, Th/To antibodies are associated with ILD preced-
ing PAH, mainly in patients with ssSSc [30].
Scleroderma-related ILD is mainly characterized by an
NSIP pattern on HRCT, followed by UIP. ILD affects
about 80% of SSc patients, but only 25–30% will develop
progressive disease within 5 years of the disease onset
(counted from the first non-RP scleroderma sign) that
will stabilise into structural damage in 4–6 years [28]. It
can be classified into limited and diffuse ILD according
to Goh’s staging system, correlating with a worse prog-
nosis for a disease extent threshold ≥20% [31].
On the other hand, PAH affects about 15% of SSc
patients, with a worse prognosis than the idiopathic
form [29]. SSc-PAH can arise from different pathogenic
mechanisms: caused by disease of the small pulmonary
arteries (group 1 PAH, mainly in lSSc patients), due to
myocardial fibrosis (rarely, group 2 PAH), or secondary
to ILD (group 3 PAH, mainly in dSSc patients) [32].
Finally, OLD can also be found in in SSc patients.
CPFE was described in 12.3% of patients, a few of whom
were non-smokers [33].
Unfortunately, the use of PFTs in SSc appears to be
less useful than in RA-ILD or IPF. This is understand-
able, taking into account that SSc has different patho-
genic mechanisms and generally a different HRCT
pattern than RA and IPF. In fact, unlike IPF, the use of
FVC as a good predictor of lung ILD severity is not
sufficiently supported, despite its wide use as a primary
outcome in clinical trials. Five validation studies were
undertaken to study the best PFT items, but in a recent
meta-analysis no items from PFTs showed good sensitiv-
ity or specificity for the early diagnosis of ILD [34].
Therefore, an HRCT should be performed in all new
diagnoses of SSc, especially for dSSc.
Also in follow up, ILD extension was associated with
FVC and DLCO only at the baseline, but not with their
decline [35]. FVC showed high variability among SSc
patients, with even amelioration from low baseline
levels: a fast decline was experienced mainly in patients
with early disease [36]. In contrast, using baseline data
from Scleroderma Lung Study I and II, DLCO provides
the best estimate of ILD measured with HRCT quantifi-
cation [37], at least in patients without PAH [38]. DLCO
is useful not only in the prediction of disease severity,
but also in the early forecast of organ damage, in the es-
timation of disease activity (DA) and correlates with DA
index in Nailfold Videocapillaroscopy (NVC) [39–42].
Obviously, DLCO can be reduced by the presence of
PAH [43]. This data reduces the specificity of DLCO in
the description of SSc-ILD and should be taken into ac-
count in its interpretation. Finally, Total Lung Capacity
(TLC) also showed good correlationas a measure of ILD
severity, but needs to be studied more extensively [31].
It is likely that, as suggested by Caron et al. in their
interesting meta-analysis [34], a composite index could
better describe SSc-ILD extension and severity than the
use of a single item alone. The Outcome Measures in
Rheumatology (OMERACT) proposed a decline of
FVC ≥ 10% or a reduction of ≥5 to < 10% with a decline
of DLCO ≥15% to define ILD progression, but these mea-
sures need to be validated [44].
A similar point can be made for the detection of PAH.
The diagnosis should be confirmed with Right Heart
Catheterization (RHC), but several PFT items can be
used for screening. An isolated reduction of DLCO ≤55%
without significant ILD and an FVC/DLCO ratio > 1.6
were found to be useful in forecasting future PAH in pa-
tients with SSc [45]. Unfortunately, DLCO can be biased
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by frequently occurring concomitant ILD that can con-
tribute to its reduction. A subdivision of DLCO into two
transfer components (membrane conductance for CO
and alveolar capillary blood volume) has been proposed
as an ideal solution. This partition can be calculated
combining DLCO with the transfer factor of the lung for
nitric oxide (TLNO) [46]. However, a large study re-
ported that the combined measurement of DLCO and
TLNO does not improve the recognition of SSc-PAH
[47]. Therefore, currently the most sensitive method to
screen SSc patients for PAH is a composite, two-step, al-
gorithm named DETECT. Items considered in this algo-
rithm are: FVC/DLCO ratio, presence of ACA and
telangiectasias, serum level of NT-proBNP and urate,
presence of right axis deviation on Electrocardiogram,
right atrium area and tricuspid velocity in echocardiog-
raphy. DETECT showed better performance than the
International European Society of Cardiology/European
Respiratory Society guidelines in the diagnosis of
SSc-PAH [48].
Mixed Connective Tissue Disease (MCTD) could be
considered in SSDs. This autoimmune disease is charac-
terized by the presence of the U1-RNP antibody and
clinical features of SSc, Systemic Lupus Erythematosus
(SLE) and Polymyositis/Dermatomyositis (PM/DM) [49].
The annual incidence of MCTD is about 1.9 per 100,000
population, with a mortality similar to general popula-
tion [49]. It is still a matter of debate whether MCTD
should be considered a separate entity or a form of Un-
differentiated Connective Tissue Disease (UCTD)/OS,
considering that the clinical picture for MCTD usually
becomes clear within 3.6 years, but the rate of differenti-
ation in other CTDs in 10 years of follow up is low (8.5%
for SLE and 6.3% for SSc) [49].
Pulmonary involvement, particularly PAH, is the major
cause of death in MCTD patients [50]. ILD in MCTD
usually shows an NSIP pattern, followed by UIP and it
occurs in about 50% of patients [51]. Out of these, 19%
show a severe, rapidly progressive ILD, with a mortality
of 20% in a follow up of 4.2 years [52]. On the other
hand, PAH occurs in about 10% of patients, associated
with antiphospholipid (APLA) and anti-endothelial cell
antibody positivity, presence of NVC alterations and RP,
but generally without significant ILD [53]. Compared to
SSc, MCTD-PAH seems to debut at a younger age and
have a comparable 1-year survival [54].
A division into three subsets of MCTD patients was
proposed: subgroup 1 with vascular damage, mainly
characterized by PAH, RP and NVC positivity, subgroup
2 with ILD and myositis and subgroup 3 (with a better
prognosis) featuring arthritis, articular erosions and
ACPA positivity similar to RA [55].
Unfortunately, evidence regarding the role of PFTs in
literature is limited. FVC and TLC proved to be stable in
MCTD over ten years, while DLCO showed a reduction
[56]. DLCO also correlated with active ILD [57], confirm-
ing its superior sensitivity in detecting ILD. Considering
that PAH and ILD in MCTD and SSC are likely to have
a similar pathogenic mechanism, a reasonable guide for
the follow up of these patients could be derived from
what is suggested for SSc.
Idiopathic inflammatory myositis
The family of Idiopathic Inflammatory Myositis (IIMs)
was traditionally used to categorize a group of auto-
immune diseases characterized by muscle weakness
caused by damage to skeletal muscle. The family are
considered PM, DM, Necrotizing Autoimmune Myositis
and Inclusion Body Myositis [58]. Except for the latter
two diseases, these conditions are widely associated with
visceral involvement, mainly of the skin and lung which
may influence the prognosis. This classification is still
under debate, with the aim of considering antibodies
positivity and including other conditions such as Anti-
synthetase Syndrome (AS) [59]. This syndrome is char-
acterized by the presence of the classic triad of myositis,
ILD and inflammatory arthritis, in which RP, mechanic
hands and unexplained fever may occur [60]. The
incidence of PM and DM is calculated at about 6–7 per
million [61] but is probably significantly underestimated
based on the clinical presentation of these patients.
Frequently, lung involvement is the unique clinical
manifestation at disease onset, but during follow up the
majority of these patients will develop the other clinical
manifestations of the disease [62, 63]. Moreover,
Sontheimer identified clinical subsets of patients without
significant muscle involvement but the presence of
typical skin involvement (Gottron’s papules and sign,
mechanic hands, heliotrope rash) and the possibility of
developing an ILD with a worse prognosis than DM
[64, 65]. This condition is named Clinically Amyopathic
Dermatomyositis (CADM). At present, validated criteria
for AS are not available. However, several patients classi-
fied as Interstitial Pneumonia with Autoimmune Features
(IPAF) for an ILD associated with Anti tRNA Synthetase
Antibodies (ATSA), should be classified for both IPAF or
AS depending on the referral centre [66, 67].
ILD affects about 65% of PM/DM patients, in a clinic-
ally relevant subset in 17–36% of patients, and proved to
be a cause of death in about 50% of patients, especially
in a subset of rapidly progressive ILD with positivity for
MDA5 antibodies [67, 68]. The most common HRCT
pattern is NSIP, but often an Organising Pneumonia
(OP), alone or an overlap NSIP-OP, can be found [69].
AS showed similar HRCT patterns, but at higher preva-
lence, with up to 90% of patients with ILD [70, 71].
AS-ILD prognosis is related to specific ATSA positivity:
anti Jo1 positive patients generally have myositis and
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arthritis with better outcome in ILD, while PL7 and
PL12 positive patients showed a worse prognosis due to
rapidly progressive ILD [72].
Few studies in the literature have investigated the role
of PAH in IIMs. It was found in 16% of PM patients,
mainly associated with Pericardial Effusion (PE) and dif-
fuse ILD [73]. However, a large cohort of PAH patients
showed IIMs in only 34 out of 5,223 patients, of which
there were only 3 without significant ILD [74]. These pa-
tients had DM, and PAH was associated with SSA/Ro
antibody positivity and, similar to SSc and MCTD, with
skin involvement and peripheral microangiopathy.
Finally, in AS a PAH was demonstrated in 16 out of 201
patients, generally associated with severe ILD. AS-PAH
patients are more likely to have polyarthralgia and long-
standing disease. The authors reported a 3-year survival
rate of 58% but they did not find any correlation with
ATSA positivity [75].
Sporadically both a restrictive disease and PAH in
IIMs could be found, mainly due to muscle weakness,
secondary to respiratory or cardiac muscle involvement.
Several case reports are reported in literature.
Regarding PFTs, an FVC% < 60 in IIMs was correlated
with a worse prognosis [76], together with Hamann Rich
presentation, CADM, older age and acute/subacute
onset of ILD [77]. FVC seems to be able to predict the
response to therapy: in one small-scale study the de-
crease in the extent of ground glass opacities correlated
inversely with changes in FVC [78]. FVC and DLCO
showed also correlation at baseline with disease extent
on HRCT (with major sensitivity for DLCO) [79]. This
data was confirmed with the CALIPER software, but
after a 1-year follow up, a significant correlation was
found only for TLC [80].
SJÖGREN’S
Sj gren’s Syndrome (SjS) is a chronic autoimmune dis-
ease involving about 0.06% of the population character-
ized mainly by Sicca syndrome, due to damage to the
lacrimal and salivary glands [81]. SjS pathogenesis is not
completely understood yet, but B cells and a T helper
type 1 and 17 responses play a key role, explaining the
potential systemic involvement (lung involvement,
vasculitis and lymphomagenesis) [82].
The most common SjS lung involvement is an ob-
structive disease with bronchial hyperresponsiveness
(42–60% of patients) often insensitive to inhaled cortico-
steroids, bronchiolitis (12–24% of patients) and BR (7–
54% of patients) [83]. The mechanism underlying these
conditions seems to be local dryness in the upper
respiratory tract, alteration in mucociliary clearance and
the presence of hyperplastic lymphoid follicles with
reactive germinal centres similar to those present in
salivary glands. This impaired muco-ciliary clearance
can expose patients to infective pneumonia, reported in
10–35% of patients [83].
ILD is present in 9–20% of patients. The most com-
mon HRCT pattern is NSIP (45%) followed by UIP,
Lymphocitic Interstitial Pneumonia and OP (16, 15, 7%
respectively, other conditions in 17%) [84].
ILD in SjS is generally stable [85], while it can be ac-
celerated when associated with hypergammaglobuline-
mia, lymphopenia, reduction of FVC and positivity for
Rheumatoid Factor (RF), SSa/Ro and SSb/La with low
sensitivity but high specificity [86].
PAH is rarely reported in literature for SjS with some
case reports. Despite these, echocardiographic elements
suggestive of PAH are reported in about 25% of patients
[87]. PAH is a severe condition, but, unlike other condi-
tions, can benefit from immunosuppressant therapy [88].
PAH was also associated in SjS patients with the pres-
ence of RP, PE, hepatic injury and high titre of RF [89].
In summary, both PAH and ILD showed contradictory
data. A possible explanation could be the evidence that
both these conditions can have their onset years before
the complete manifestation of SjS [83, 89]. Moreover, it
is possible that patients with severe lung involvement
that could have an impact on their prognosis, tend to be
referred to a specialist perceived to be more relevant to
their condition, bypassing the rheumatologist.
Regarding PFTs, few data are reported in the literature.
A common finding is the reduction of Vital Capacity
(VC), Forced Expiratory Volume at 1 s (FEV1), FEV1/VC
ratio and DLCO, signalling an obstructive disease, even
in non-smoking patients [90]. Obviously, an overlapping
restrictive disease should be taken into account. During
ILD, good correlation was found at baseline between
DLCO and TLC and the scores of ground-glass attenua-
tions [91].
Systemic lupus erythematosus
SLE is a chronic autoimmune disease potentially able to
cause a systemic involvement (skin, kidney, blood, cen-
tral and peripheral nervous system, etc) characterized by
a deposition of immune complexes leading to organ
damage [92]. Although lung involvement is not consid-
ered separately in SLE classification criteria [93], the
disease is able to damage the whole respiratory tract at
each level [94]. Upper airway involvement includes nasal
ulcers (considered in SLE classification criteria), mucosal
inflammation and sporadically severe airway obstruction
with respiratory failure [94]. The most common involve-
ment is pleurisy (also considered in SLE criteria), that
can involve up to 60% of patients [95]. Another
extra-parenchymal manifestation of SLE is Shrinking
Lung Syndrome (SLS), a rare complication characterized
by a restrictive disease without parenchymal involve-
ment due to diaphragmatic dysfunction. This condition
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could affect up to 10% of patients [96]. ILD affects about
15% of SLE patients, generally with NSIP pattern [97].
SLE-ILD patients often showed a better prognosis than
that seen in idiopathic forms or other CTDs. Severe par-
enchymal manifestations are Acute Lupus Pneumonitis
(ALP) and Diffuse Alveolar Damage (DAD). The first is
an acute form that involves about 1–4% of patients with
an active flare of the disease and SSa/Ro positivity [98]
that is hard to distinguish from infective pneumonia.
DAD is a life-threatening complication that affects about
2% of patients and is characterized by damage to the
alveolar-capillary membrane, generally associated with
positivity for antiphospholipid antibodies (APLA) [99].
SLE is also the second autoimmune cause of PAH,
with a prevalence of 0.6–17% of patients [100]. Multiple
pathogenic pathways can be implicated in pathogenesis
(vasculitis, pro-thrombotic state secondary to the pres-
ence of APLA, cardiac and valvular dysfunction, ILD
and SLS). Therefore, SLE-PAH can be potentially classi-
fied in each PAH group, but increasing evidence sug-
gests the utility of immunosuppressive therapy (jointly
with vasodilators) for its management [94, 100].
Regarding PFTs, little evidence is available, probably
due to the fact that severe lung involvement is rare and
usually acute, while a chronic disease generally shows a
slow decline and a good prognosis.
A reduction in DLCO is reported in about 38% of
asymptomatic SLE patients, but after a follow up period
of 9 years none of these patients developed a lung dis-
ease [101], therefore this reduction seems not to be use-
ful in predicting future lung involvement in SLE
patients. A reduction in Maximum Voluntary Ventila-
tion without a significant impairment in FEV1 and FVC
was also noted in SLE patients, leading to the conclusion
that fatigue, a common symptom in the disease, could
also involve the respiratory muscles [102]. Regarding
6MWT, a Heart Rate Recovery (difference between
Heart rate at the end of 6MWT and after 1,2 and 3min
of rest) < 16 was associated with a worse prognosis in
patients with CTD-PAH (group composed of patients
with lSSc, dSSc, MCTD, SLE) [103].
Other conditions
The prevalence of lung involvement in UCTD has not
been adequately studied. The major problem is a lack of
consensus on classification criteria for UCTD and
possible selection bias. Indeed, UCTD can represent an
incomplete form or an early onset of CTD and it is rea-
sonable to suppose that individual patients are usually
referred to a specialist in the specific organs involved. In
2015, classification criteria for Interstitial Pneumonia
with Autoimmune Features (IPAF) were proposed, in
order to recruit these forms with ILD involvement [104].
Currently no prospective data are available in literature,
but several retrospective studies report a heterogeneous
population [66]. An improvement of these criteria could
be useful for the earlier recruitment of CTD-ILD, in
order to exploit a window of opportunity before the
development of a structural damage.
An interesting speculation can also be made regarding
Antiphospholipid Syndrome (APS). This is an auto-
immune disease characterized by the presence of venous/
arterial thrombosis or obstetrical morbidity associated to
the positivity for APLA and Lupus Anticoagulant (LAC).
APS often overlaps with CTDs (mainly SLE) and is associ-
ated with PAH and pulmonary embolism [105]. As already
mentioned, the presence of APL can predict PAH in SLE
[99]. Sporadically, ILD in APS was reported. Conversely, it
Table 1 Risk factors for Chronic Pulmonary Disease in CTDs
DISEASE ILD OLD PAH
RA Older age; male sex, smoking history; ACPA positivity,
LDH, longstanding or persistently active disease;
rheumatoid nodules, articular erosions, genetic
predisposition (HLA linked)
Smoking, older age
SSDs Scl70, Th/To positivity, dSSc, smoking, older age,
rapidly progressive disease.
ACA, LAC, and anti RNA polymerase I, II, III, AECA
positivity, older age, RP, NVC positivity; telangiectasias,
seric NT-pro-BNP and urate, RAD, RAA, TV, PE
IIMs Cutaneous manifestations; telangiectasias, RP, ATSA
positivity (rapidly progressive for non-Jo1 positivity);
older age, acute/subacute onset, CADM, Hamann
Rich presentation correlated with worse prognosis
Cutaneous manifestations, peripheral microangiopathy,
positivity for SSA/Ro, severe ILD, polyarthralgia,
longstanding disease
SjS Hypergammaglobulinemia, lymphopenia, RF,
SSA/Ro, SSB/La positivity
Sicca syndrome, smoking RP, PE, hepatic injury, RF positivity
SLE APLA, cardiac or vascular dysfunction, ILD, SLS
ACA anticentromeric antibodies, ACPA Anti Citrullined Peptides Antibody, AECA Anti Endothelial Cell Antibody, ATSA Anti tRNA Synthetase Antibodies, CTDs
Connective Tissue Diseases, dSSC diffuse Systemic Sclerosis, HLA Human Lymphocitic Antigen, IIMs Idiopathic Inflammatory Myopathies, ILD interstitial Lung
Disease, LAC Lupus Anticoagulant, LDH Lactic Dehydrogenase, OLD Obstructive Lung Disease, PAH Pulmonary Artery Hypertension, PE pericardial Effusion, RA
Rheumatoid Arthritis, RAA Right Atrium Area in echocardiography, RAD Right Axis deviation in electrocardiogram, RF Rheumatoid Factor, RP Raynaud
Phenomenon, SLE Systemic Lupus Erythematosus, SjS Sjӧgren Syndrome, SSDs Scleroderma Spectrum Disorders, TV tricuspid velocity in echocardiography, SLD
Shrinking Lung Syndrome
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should be noted that APLA are frequently discovered in
IPF patients, and a LAC positivity was found in about 20%
of patients [106]. Moreover, these patients frequently had
vascular thrombosis, therefore satisfying classification cri-
teria for APS [107]. The percentage of LAC positivity in
IPF patients appears to be very high, considering the inci-
dence of LAC positivity in the general population (1–5%,
[108]) and in SLE (34.1%, [109]), potentially explaining the
pro-thrombotic state evidenced in the disease [110].
Conclusions
The evolution of CTD-ILD varies significantly in each
patient: some identified risk factors for diagnosis and
prognosis are reported in Table 1. Considering the
different pathogenic pathways and manifestations of
lung involvement in CTDs, a translation of the PFTs
indications and their significance from IPF to CTDs
should be made with caution. Table 2 summarizes the
PTFs’ significance in CTDs.
The high incidence of ILD in CTD suggest that PFTs,
jointly with physical examinations, should be performed
in all new diagnoses and repeated periodically regardless
of referred symptoms. In RA, PFTs can be useful for
highlighting an asymptomatic ILD before its clinical
onset [3], and it could be useful to tailor appropriate
immunosuppressive drugs. Similar data were reported
for SSc [2], but not for SLE [101]. In patients with SSDs
and IIMs, the frequency and the severity of chronic lung
involvement suggest that it would be wise to perform an
HRCT jointly with PFTs in all new patients, but PFT
items appear to be less accurate than in IPF in the
description of lung function during the course of the
disease or in response to treatment. Considering this, a
composite index could be more useful than the evalu-
ation of a single item.
In view of this, more exhaustive studies regarding risk
factors together with PTFs could be useful for early
diagnosis and treatment before the stabilization of a
structural damage, improving both patient survival and
quality of life.
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Table 2 Significance of PFTs in Chronic Lung involvement due
to CTDs
Disease Items Correlation
RA
ILD Decline of FVC≥ 10%
from 68.7 or any time
from baseline
Decline of DLCO%≥ 10%
from 48.1 or any time
from baseline
Mortality
DLCO%≤ 54
FVC decline ≥10%
DLCO decline ≥15%
Progression
SSDs
ILD Decline of FVC ≥10%
or comprised between
5 and 10% with a
decline of DLCO≥15%
Progression
DLCO < 80 Clinical and NVC DA
PAH DLCO ≤55 diagnosis
FVC/DLCO> 1.6 diagnosis
IIMs
ILD FVC≤ 60 prognosis
TLC Disease extent in FU
SjS
OLD Reduction of VC, FEV1,
FEV1/VC, DLCO
Diagnosis and prognosis
ILD DLCO, TLC Correlation with disease
extent
SLE
PAH HRR < 16 prognosis
DA Disease Activity, DLCO diffusing capacity for carbon monoxide, FEV1 Forced
Expiratory Volume in 1 s, FVC forced vital Capacity, HRR heart Rate Recovery,
IIMs Idiopathic Inflammatory Myopathies, ILD Interstitial Lung Disease, NVC
Nailfold Videocapillaroscopy, PAH Pulmonary Artery Hypertension, PFT
Pulmonary Function Test, RA Rheumatoid Arthritis, SjS Sjögren Syndrome, SLE
Systemic Lupus Erythematosus, SSDs Scleroderma Spectrum Disorders, TLC
Total Lung Capacity, VC Vital Capacity
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